115 related articles for article (PubMed ID: 9093727)
21. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
23. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
Letendre L; Noel P; Tefferi A; Solberg LA; Gastineau DA; Hoagland HC
Am J Clin Oncol; 1995 Oct; 18(5):382-4. PubMed ID: 7572751
[TBL] [Abstract][Full Text] [Related]
24. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
25. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
Visani G; Petti MC; Cenacchi A; Manfroi S; Tosi P; Spadea A; Latagliata R; Amadori S; Mandelli F; Tura S
Leuk Lymphoma; 1995 Nov; 19(5-6):447-51. PubMed ID: 8590845
[TBL] [Abstract][Full Text] [Related]
26. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
27. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
[TBL] [Abstract][Full Text] [Related]
28. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
[TBL] [Abstract][Full Text] [Related]
29. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
30. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology.
Pein F; Tournade MF; Zucker JM; Brunat-Mentigny M; Deville A; Boutard P; Dusol F; Gentet JC; Legall E; Mechinaud F
J Clin Oncol; 1994 May; 12(5):931-6. PubMed ID: 8164044
[TBL] [Abstract][Full Text] [Related]
31. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
34. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
[TBL] [Abstract][Full Text] [Related]
35. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
[TBL] [Abstract][Full Text] [Related]
36. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
[TBL] [Abstract][Full Text] [Related]
37. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Bolaman Z; Köseoğlu M; Ayyildiz O; Kadiköylü G; Sönmez HM; Demir S; Müftüoğlu E
Haematologia (Budap); 2002; 32(1):49-57. PubMed ID: 12243555
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of cytosine arabinoside, carboplatin and etoposide chemotherapy in the treatment of relapsing and refractory non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Acta Haematol; 1996; 96(1):36-40. PubMed ID: 8677759
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
40. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]